Introduction
Congenital hyperinsulinism (HI) is the most common cause of persistent hypoglycemia in infants and children (1). Six genetic loci have been associated with the disorder. The most common of these disorders are due to inactivating mutations of the Sulfonylurea receptor 1 (SUR1) and Kir6.2 subunits of the ß-cell ATP-dependent potassium (K ATP ) channel or to activating mutations of glutamate dehydrogenase and glucokinase.
Recently, several children have been described with a recessively inherited form of HI that is associated with deficiency of a mitochondrial fatty acid β-oxidation enzyme, short-chain 3-hydroxyacyl-CoA dehydrogenase (SCHAD) encoded by the HADH gene on 4q (2) (3) (4) . SCHAD catalyzes the third step in the β-oxidation cycle for medium and short chain 3-hydroxy fatty acyl-CoAs. Children afflicted with SCHAD deficiency have recurrent episodes of hypoglycemia that can be prevented by treatment with diazoxide (2, 3) and also have characteristic accumulations of fatty acid metabolites, including plasma 3-hydroxybutyrylcarnitine and urinary 3-hydroxyglutaric acid (2, 3) . This form of abnormal insulin regulation is unique, because other genetic disorders of mitochondrial fatty acid oxidation do not cause hyperinsulinism (5) . In addition, the genetic defect in SCHAD deficiency is expected to impair, rather than increase, the production of ATP which normally serves as the triggering signal for insulin release. An important clue to the mechanism of insulin dysregulation in SCHAD deficiency has been recently provided by the report that affected children are sensitive to protein-induced hypoglycemia (6).
Elucidating the mechanism of insulin dysregulation and, especially, the cause of the hypersensitivity to protein induced hypoglycemia in SCHAD deficiency may provide important insight into the regulation of insulin secretion in normal individuals. The present report describes studies of a mouse model of SCHAD deficiency that was developed by ablation of the mouse hadh gene. The results suggest that the dysregulation of insulin secretion associated with SCHAD deficiency is due to an activation of GDH enzyme activity, reflecting the loss of an inhibitory proteinprotein interaction of SCHAD upon GDH which has not previously been recognized.
Experimental Procedures:
SCHAD (hadh) gene targeting-hadh-/-mice were generated by homologous recombination in R1 mouse embryonic stem (ES) cells. Genomic DNA corresponding to the Sv129/J mouse hadh gene was isolated in overlapping bacteriophage lambda clones (Stratagene) and a P1 clone (Incyte Genomics, Palo Alto, CA), and the nucleotide sequences of the exons and flanking intronic sequences were determined. The knockout targeting vector was constructed in the pPNT vector. A 4.2 kb fragment from immediately upstream of exon 1 and a 0.8 kb Pst I fragment from downstream of exon 1 of the hadh gene were used to flank the neomycin resistance cassette in the targeting construct. The linearized targeting construct was electroporated into R1 ES cells, and the ES cells were subjected to positive and negative selection with G418 (250 µg/mL, GibcoBRL) and 2-deoxy-2-fluoro-β-D-arabinofuranosyl)-5-iodouracil, respectively. Ninety-five clones survived selection and were subsequently screened by a polymerase chain reaction (PCR) assay to identify homologous recombinants (primer sequences and PCR conditions are available upon request). One homologous recombinant was detected and confirmed by Southern blotting. The clonal hadh knockout ES cell line was injected into C57/BL6 blastocysts followed by implantion into pseudopregnant female mice to generate chimeras. High percentage (~80%) male chimeras were bred to NIH Black Swiss females to generate hadh +/-heterozygotes.
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TGA GCTATG GCG TTC GTG AAC A3'and 5'TCT GCA ACT TTG CAC GCA CAA CTG TGT3' for hadh+/+, and 5'AAT CAG CAG TGA GAG AGC CAC AGG CAA3' and 5'TGC TAA AGC GCA TGC TCA CAG ACT GC3' for hadh-/-. The PCR assay generated products of 359bp for the wildtype hadh allele and 800bp for the hadh knockout allele.
RT-PCR and Western
Blot Analysis-For RT-PCR analysis, total RNA was isolated from fresh tissue including pancreatic islets, liver, kidney and brain using Trizol (Invitrogen). cDNA was generated by reverse transcription using Superscript First-strand Kit (Invitrogen). The sequences of primers for PCR amplification of hadh and GAPDH mRNA were: for hadhforward, 5'CCA CCA GAC AAG ACC GAT -3'; for hadh-reverse, 5'TCA ATG AGG TAT GGC ACC AA -3'; for GAPDH-forward, AAC TTT GGC ATT GTG GAA GG -3'; and for GAPDH-reverse, GGA TGC AGG GAT GAT GTT CT -3'. PCR products of 208 bp for hadh and 132 bp for GAPDH were generated. Western blots were performed on whole tissue protein extracts (pancreatic islets, liver, kidney and brain) to detect SCHAD.
Briefly, approximately 100 mg of freshly harvested tissue (liver, kidney and brain) was washed with PBS and homogenized in PBS plus 1% Triton. A total 15 µg of protein including fresh isolated islets was loaded in each lane of 10% SDS-PAGE mini-gels and after electrophoresis proteins were transferred to nitrocellulose membranes. A chicken polyclonal anti-SCHAD antibody (Abcam), and a rabbit anti-Actin antibody (Sigma) were used as the primary antibodies; a goat polyclonal anti-chicken IgY Horseradish peroxidase conjugate (Abcam) and a donkey anti-rabbit IgG-Horseradish peroxidase conjugate (Amersham) were used as the secondary antibodies. Membranes were blocked and incubated with antibody in 5% milk in PBS-Tris buffer and washed in PBS-Tris + 0.02 % Tween-20. Antibody-protein complexes were detected with the ECL reagent (Amersham).
As shown in Figure 1 Panel A, B, C, hadh gene, hadh cDNA and SCHAD protein were successfully deleted.
SCHAD and GDH gene expression-Total RNA were isolated from islets, liver and kidney using the Trizol (Invitrogen) method. For the reverse transcription reaction, 40 µl PCR reaction efficiently converts 1.0 µg total RNA to cDNA (Invitrogen). The sequences of primers were as indicated: for SCHAD-forward: CCA CCA GAC AAG ACC GAT TT; for SCHADreverse: TCA ATG AGG TAT GGC ACC AA; for GDH-forword: CTA TGG AGC TGG CCA AGA AG; for GDH reverse: CCT ATG GTG CTG GCA TAG GT; for GAPDH-forward: AAC TTT GGC ATT GTG GAA GG; and for GAPDH-reverse: GGA TGC AGG GAT GAT GTT CT. Quantitative Real-Time PCR (Applied Biosystems SYBR Green Master Mix Kit) was carried out in low reaction volumes in 384-well plates using 7.5 µl 2X Syber green master mix, 0.2 µl primer (10 µM), 1 µl cDNA and water added to bring the final volume of 15 µl. Thermal cycle condition were: at 50°C for 2 min, at 95°C for 10min, followed by 40 cycles at 95°C for 15 sec and at 60°C for 1min. Experiments were performed with the 7900HT sequence detection system (Applied Biosystems). Islets mRNA level were calculated GAPDH as standard and internal controls.
Islet immunohistochemistry-8 to 12 week-old hadh-/-and +/+ male mice were anesthetized and transcardially perfused with 10 ml of saline, followed by 50 ml of fixative containing 4% paraformaldehyde and 0.125% glutaldehyde. The slices of pancrease were treated with a mixture of 1% bovine serum albumin, 5% normal goat serum and 0.3% Triton-X 100 in 0.01M phosphate buffer (PBS, pH 7.4) for 60 min at room temperature before incubated with a goat anti-glucagon antibody (1:500 in PBS; Santa Cruz) and guinea pig anti-insulin antibody (1:500 in PBS) for 90 min at room temperature and then overnight at 4 ºC. The slices were by guest on November 19, 2017 http://www.jbc.org/ Downloaded from subsequently incubated with Alexa Fluor 594-conjugated donkey anti-goat IgG (Molecular Probes) and Cy 2-conjugated donkey anti-gunea pig IgG (Jackson Lab). Both secondary antibodies were diluted at 1:250 in PBS, containing Hoechst (a nuclear dye). Confocal images were acquired under Olympus Fluoview 1000 System (Olympus) at a step of 0.5 µm on the Z-axis. Consistent confocal settings were optimized and remained unchanged during the imaging of both hadh-/-and +/+ slices.
Oral amino acid tolerance test (OAATT), oral glucose tolerance test (OGTT) and insulin tolerance test (ITT)-All experiments were carried out in male mice, age 10 to 12 weeks. OAATT's were performed on 2 hours fasted mice using an amino acid mixture (composition described previously (7)) which was administered via oral gavage with dose of 1.5g/Kg of body weight. OGTT's were performed on 24 hours fasted mice using 2g/Kg of glucose via oral gavage. ITT's were performed on 2 hours fasted mice using human insulin (1 unit/Kg intraperitoneal). Blood samples were taken from the tail at the indicated times. Plasma glucose concentrations were measured using a Freestyle flash glucose meter and insulin was measured using an ELISA kit (ALPCO).
Metabolite assays-Acylcarnitine species were analyzed in mouse plasma as butylated derivatives using flow injection tandem mass spectrometry that has been validated for clinical use in humans (8) . Data collection was performed in a multiple reaction monitoring system using the parent ions of the fragment with m/z 85 as reference. Quantitation of acylcarnitine was achieved using a series of stable-isotope labeled internal standards (8) . Urine organic acids were analyzed by gaschromatography/mass spectrometry as trimethylsilyl derivatives with full scan data collection for positive peak identification. This assay is also validated for clinical use in humans (9) . Plasma 3-hydroxy fatty acids were measured using stable isotope dilution gaschromatography-mass spectrometry (10).
Mouse islet isolation, insulin secretion and cytosolic Ca
2+ measurements-Isolation of pancreatic islets, perifusion, and insulin assays were carried out as previously described (11) . In brief, islets were isolated by collagenase digestion and cultured with 10 mM glucose in RPMI 1640 medium (Sigma) for 3 to 4 days. Islets were perifused in a Krebs-Ringer bicabonate buffer (KRBB) with 0.25% BSA at a flow rate of 2 mL/min. Insulin was measured by radioimmunoassay. [Ca 2+ ] i was measured by dual wave length fluorescence microscopy using a Zeiss AxioVision system as described previously (7) .
ATP, ATP/ADP ratio and intracellular amino acid measurements-Batches of 100 isolated cultured islets were pre-incubated with KRBB for 60 min and then incubated with glucose-free buffer as basal; with glutamine/leucine (2/0.46 mM) in combination with or without additional 1.25 mM alanine; and with 12 mM AAM with or without 25 mM glucose and 25 mM glucose alone for another 60 min. Measurements of ATP, ATP/ADP ratio, intracellular amino acids and insulin and glucagon release were described previously (12) .
[U-
14 C]glutamine oxidation-[U-14 C]glutamine (NEN-Life Science Products, UK) oxidation was measured in cultured islets as described previously (13, 14) .
GDH and SCHAD enzyme activity-Tissue (freshly isolated islets, liver and kidney) was homogenized in phosphate buffer (5 mM Na 2 HPO 4 , 5 mM K 2 HPO 4 , 1 mM EDTA, 1% Triton X-100, pH 7.4). GDH and SCHAD activities were assayed spectrophotometrically at 340 nm by monitoring oxidation of NADH (11, 15, 16 ) in a 384-well plate format in a 25 µl reaction volume using a SpectraMax M5 (Molecular Devices). Because of limited tissue, studies of islet GDH kinetics were carried out in the presence of either maximal (100 µM) or submaximal stimulatory (10 µM for Km) concentrations of ADP. Km and Vmax for alpha-ketoglutarate were calculated by GraphPad Prism. For His-SCHAD/GDH mixing experiments, the molar concentration of GDH in liver was estimated from the maximal ADP stimulated activity, using bovine GDH (Sigma) as a standard. Different amounts of His-SCHAD were added to the homogenate prior to assays of GDH kinetics.
Immunoprecipitation
by anti-SCHAD antibody-Fresh liver mitochondria from both hadh+/+ and hadh-/-mice were isolated using a Mitochondria Isolation Kit (Qiagen Inc. USA). Sample sizes of 60 mg per preparation were found to be optimal. All steps were performed at 4 o C. Mitochondria pellets were lysed in PBS with 1% Triton and the protein concentration was adjusted to 5 µg/µl. Immunoprecipitation was performed using the Seize Primary Mammalian Immunoprecipitation Kit (Pierce, Rockford, IL). Briefly, 100 µg of affinitypurified anti-SCHAD antibody (Abcam, Inc. Cambridge, MA) was bound to AminoLink Plus Coupling Gel (200 µl of pre-washed 50% gel slurry). The antibody-coupled gel was thoroughly washed and divided into two columns. Mitochondrial extracts were mixed 1:1 with PBS to a volume 400 µl (1 mg protein) and then added to the antibody-coupled gel. After incubation with gentle mixing for 16 hours at 4 o C, the gel was washed with PBS-Tris buffer and the immunoprecipitated antigen was eluted in elution buffer. Western blot analysis was performed using a rabbit polyclonal anti-GDH antibody (Abcam, Inc. Cambridge, MA).
His-SCHAD pull-down assay-Recombinant His-tagged SCHAD protein was expressed in E. coli using the pET 20 (b+) expression vector containing a full-length mouse hadh cDNA and a C-terminal His Tag (Novagen, USA). The Histagged SCHAD protein was purified using NiHis Columns (Novagen, USA) by standard methods. Protein pull-down experiments were performed using an Aminolink Plus Immobilization Kit (Pierce, Rockford, IL). Briefly, His-tagged SCHAD protein was covalently cross-linked to the aminolink agarose resin. Liver tissue (0.5 g wet weight) from hadh+/+ and -/-mice was homogenized using 20 volumes of M-PER mammalian protein extraction reagent (Pierce, Rockford, IL) and centrifuged at 2000g for 10 minutes. The supernatant was mixed with an equal volume of (Mammalian Protein Extraction Reagent; M-PER) binding buffer and incubated with the SCHAD-linked amino link resin at 4 o C overnight. The resin was centrifuged (2000g) after incubation and washed with (0.5 mL) (M-PER) washing buffer and bound proteins were eluted with (200 µL) of (M-PER) elution buffer. Western blot analysis of the eluted proteins was performed and the blot was probed with a polyclonal anti-GDH antibody.
Proteomic analysis of pull-down proteins by recombinant SCHAD proteinMassspectrometry analysis of the protein complexes from the pull down assay using His-tagged SCHAD protein was performed at the protein core facility of the Department of Pathology & Laboratory Medicine at the University of Pennsylvania. The protein complex was digested with trypsin followed by tandem mass spectrometric analysis of the peptide sequences. Identified sequences were matched to the proteins using Scaffold protein identification software v 2.0.
Immunoprecipitation by anti-GDH antibody-200 μl of a 50% suspension of protein A beads (Invitrogen) and 200 μl of Rabbit anti-GDH antibody (Rockland) were incubated for 2 hours at room temperature by gently mixing, then washed 5 times with 400 μl of PBS-T buffer. Islets from hadh-/-and +/+ mice were homogenized using PBS buffer plus 1% Triton. 1 mg (400 µl) of islets lysates protein were then incubated at 4 o C overnight with protein A beads bound with anti-GDH antibody. After washing 5 times with PBS-T buffer, the samples were eluted with elution buffer (Pierce). SCHAD protein was detected by Western Blot using anti-SCHAD antibody.
Materials-All chemicals were from Sigma except as otherwise indicated.
Data Analysis-All the data are presented as mean ± S.E.. Student t test was performed when two groups were compared. Repeated measures of ANOVA were performed when multi groups were compared. Differences were considered significant for p<0.05.
Results
hadh gene and SCHAD protein deletion-As shown in Figure 1 (Panel A, B, C), hadh gene, hadh cDNA and SCHAD protein were successfully deleted in all tissues, including liver, kidney, brain, and isolated pancreatic islets.
In vivo metabolite changes resulting from SCHAD deletion-As shown in table 1, hadh-/-mice showed abnormalities of plasma and urinary metabolites similar to those found in children with SCHAD deficiency. In the fed state, there was a four-fold elevation of plasma 3-hydroxy-butyrylcarnitine in hadh-/-mice compared with controls, similar to values reported in children with SCHAD deficiency (2,3). The remaining profile of acylcarnitines from C2 to C18 was indistinguishable from normal (data not shown). After 24 hours of fasting, levels of 3-hydroxy-butyrylcarnitine increased in control, but not in hadh-/-mice, although levels remained higher in -/-mice. 24 hours of fasting also resulted in increased plasma 3-hydroxy-fatty acids of C6 and C8 species in hadh-/-mice. 3-hydroxy-fatty acids of chain lengths C10 to C18 were indistinguishable from normal (data not shown). Urine from hadh-/-mice had increased excretion of 3-hydroxyglutarate, which has been reported in affected SCHAD deficient children, and also of glutaconic acid, which is an unstable metabolite derived from glutaconyl-CoA, an intermediate of glutaryl-CoA reduction. This has not been previously detected in affected children but is seen in some patients with glutaryl-CoA dehydrogenase deficiency (17) . Pancreatic histology in the hadh-/-mice showed abnormalities similar to that of SUR1 knockout (SUR1-/-) islets; i.e., glucagon-staining alphacells were distributed throughout the islet, rather than being restricted to the outer margin ( Figure  1 , panel D). Glucagon content was comparable in -/-vs. +/+ islets (2.6±0.6 vs. 2.4±0.8 ng/µg islets protein, n=10, p>0.05).
Amino acid, glucose and insulin sensitivity in vivo-Because hypersensitivity to amino acid stimulation of insulin release has been reported to be part of the phenotype of children with SCHAD deficiency (6), we examined responses of hadh-/-mice to an amino acid challenge in vivo. As shown in Figure 2A and 2B after 2 hours of fasting, basal glucose was significantly lower and basal insulin significantly elevated in hadh-/-mice. Following oral amino acid stimulation, there were significant decreases in glucose and increases in plasma insulin in the hadh-/-mice, whereas there were no significant changes in glucose or insulin levels in control mice. This observation is consistent with the observation of protein-sensitive hypoglycemia in children with SCHAD deficiency.
As shown in figure 2 (panel C), hadh-/-mice also demonstrated lower plasma glucose levels than controls after 24 hours fasting. An oral glucose tolerance test in these 24 hour fasted mice demonstrated no difference in glycemic responses between knockout and controls (areas under the curve using basal glucose level as baseline were similar: -/-: 10545±1036 vs. +/+: 12200±1587, p>0.05). The increases in plasma insulin following oral glucose (panel D) were also similar, despite the fact that fasting glucose levels in -/-mice were significantly lower and insulin levels were significantly higher than in controls (areas under the curve similar using basal level as baseline, -/-: 77±22 vs. +/+: 75±21, p>0.05).
As shown in Figure 2E , the insulin/glucose ratios in hadh-/-mice were significantly higher in both the 2 hour and 24 hour fasted conditions. After oral amino acid challenge, the elevated insulin/glucose ratio increased even further in -/-mice, but not in controls. In contrast, glucose administration partially corrected the inappropriately elevated insulin/glucose ratio in -/-mice. The degree of fasting hypoglycemia in hadh-/-mice was more severe than that of SUR1-/-mice, but not as severe as in RIP H545Y huGDH gain of function transgenic mice (12, 18) . Female hadh-/-mice had fasting and non-fasting hypoglycemia similar to male mice (data not shown).
As shown in Figure 2F , there was no evidence of increased insulin sensitivity in 2 hours fasted hadh-/-compared to +/+ mice. The slopes of the decrease in glucose levels in the insulin tolerance test were similar (-/-vs. +/+, -1.27±0.02 vs. -1.28±0.02, p>0.05).
The knockout mice had a faster recovery rate (slopes from 60 min to 120 min were 0.49±0.03 for -/-and 0.26±0.02 for +/+, p<0.01), indicating that the counterregulatory hormone secretion in response to hypoglycemia was not impaired in hadh-/-mice.
Amino acid (AASIS) and leucine stimulated insulin secretion and cytosolic calcium ([Ca

2+
] i ) responses in isolated islets-To investigate the mechanism of insulin dysregulation and hypersensitivity to amino acids in hadh-/-mice, we first examined insulin responses of isolated cultured islets to stimulation by a mixture of amino acids. As shown in Figure 3A , islets from hadh-/-mice showed dramatic sensitivity to ramp stimulation with an amino acid mixture (AAM), whereas both hadh+/+ and hadh+/-islets (data not shown) had no response. The threshold for AASIS in hadh-/-islets was 2.64 mM, which is less sensitive than we previously found in transgenic islets expressing the human H454Y GDH activating mutation (1.68 mM) (12) . As shown in Figure 3B , in the presence of 2 mM glutamine, hadh-/-islets had a lower threshold (1.5 vs. 3 mM) and increased maximum for leucine stimulation of insulin secretion compared to +/+ islets, suggesting an increased sensitivity of GDH to allosteric activation by leucine.
Hypersensitivity to AASIS also occurs in the SUR-/-mouse model of hyperinsulinism, but not through leucine stimulation of GDH. Instead, it reflects a specific effect of glutamine to amplify insulin release in the presence of the elevated levels of cytosolic [Ca 2+ ] i resulting from the absence of K ATP channel activity (7) . Figure 3C shows that, unlike SUR1-/-islets, hadh-/-islets had normal basal levels of cytosolic [Ca 2+ ] i . Hoverer, the hadh-/-islets were very sensitive to stimulation of [Ca 2+ ] i by a mixture of amino acids (3.5 mM AAM plus 0.5 mM glutamine) ( Figure 3C) ; in control islets, in contrast, an AAM stimulated [Ca 2+ ] i to rise only when GDH had been activated by pre-exposure to 10 mM 2-amino-2-norbornane-carboxylic acid (BCH), a non-metabolizable leucine analogue ( Figure 3B ).
The role of leucine, glutamine and alanine on insulin secretion-The above data suggested that increased sensitivity to leucine and amino acid stimulated insulin secretion in hadh-/-islets involved activation of GDH. As shown in Figure 4A , [U-
14 C]glutamine oxidation was increased two-fold in hadh-/-islets, providing further evidence of increased GDH activity. However, hadh-/-islets showed no insulin response to stimulation with glutamine alone (data not shown). This differed from the brisk response to glutamine we previously observed in by guest on November 19, 2017 http://www.jbc.org/ Downloaded from the mouse model of GDH HI using transgenic islets expressing the H454Y huGDH activating mutation (12) . To investigate why the complete amino acid mixture was more potent than glutamine alone to stimulate insulin secretion in hadh-/-islets, we performed further experiments with combinations of individual amino acids. As shown in Figure 4B , when glutamine was removed from the total mixture of amino acids, insulin secretion was decreased by 90% in hadh-/-islets, indicating that glutaminolysis played an important role in the response to the amino acid mixture. When glutamine and leucine were both removed from the amino acid mixture, hadh-/-islets were completely unresponsive, indicating that GDH activation by leucine was essential to the release of insulin ( Figure 4B ). The response to a ramp combining glutamine (2mM) plus leucine (0.46 mM) in the same concentrations as in the amino acid mixture was only 40% of that previously observed with the complete amino acid mixture ( Figure 3A ). With addition of alanine to the glutamine/leucine combination (maximum concentration, 1.25 mM), the insulin response became equal to that obtained with the complete 19 amino acid mixture, indicating that the other 16 amino acids did not contribution to insulin release. The additive effect of alanine could not be reproduced by addition of 1.25 mM methyl-pyruvate, monomethyl-succinate, α-ketoisocaproate, or acetyl-carnitine (data not shown).
As shown in Figure 4C , measurements of [Ca 2+ ] i in -/-islets indicated that addition of alanine (1.25 mM) also enhanced the calcium response to the combination of glutamine plus leucine (2 and 0.46 mM). This additive effect of alanine was not due to formation of additional glutamate for the GDH reaction via transamination, because increasing the glutamine concentration of the glutamine/leucine mixture by an additional 1.25 mM was not as effective as alanine (data not shown). The alanine effect was partially reproduced by addition of 4 mM glucose, which suggests that providing additional pyruvate from either glucose or alanine was potentiating glutamine oxidation. Addition of alanine to glutamine/leucine stimulation of H545Y huGDH transgenic islets (12) had no effect on [Ca 2+ ] i (Figure 4D ), suggesting that glutaminolysis is already maximal in these islets.
Glucose stimulated insulin secretion (GSIS) and [Ca 2+ ] i responses-Since the in vivo data revealed no evidence of abnormal insulin responses to glucose stimulation in hadh-/-mice, we further examined GSIS in perifused islets. Unlike the hypersensitivity of -/-islets to AASIS, there were no differences between hadh-/-and +/+ islets in response to a glucose ramp stimulation ( Figure 5A ). Addition of a mediumchain fatty acid, 1 mM octanoate, potentiated GSIS equally in -/-and +/+ islets. Addition of a long-chain fatty acid, 0.25 mM palmitate, had a slight inhibitory effect on GSIS, that was identical in -/-and +/+ islets ( Figure 5B ). As shown in Figure 5C , hadh-/-and +/+ islets showed similar basal cytosolic calcium ( Amino acid and glucose metabolism and amino acid profiles in hadh-/-isolated isletsTo further examine the apparent activation of GDH activity in hadh-/-islets, we determined the effects of glucose and amino acids on intracellular amino acid levels and insulin responses in batch incubated hadh-/-and +/+ islets. In the absence of glucose, basal islet ATP content was elevated and there was a trend toward increased ATP/ADP ratio in -/-islets, consistent with an increase in basal amino acid oxidation as a result of GDH activation. Consistent with this observation, -/-islets had significantly lower aspartate and glutamate levels than controls under glucose-free conditions. This apparent increase in amino acid oxidation under basal conditions was insufficient to stimulate insulin release. A combination of glutamine and a low concentration of leucine stimulated insulin secretion in hadh-/-but not in control islets. Under this condition also, the hadh-/-islets had significantly lower levels of aspartate and the sum of alanine, aspartate, glutamate and glutamine was lower than in control islets. In hadh-/-islets, the addition of 1.25 mM alanine to the glutamine/leucine mixture further increased both insulin release and the ATP/ADP ratio to the same level as stimulation with 12 mM AAM. Under both conditions hadh-/-islets had lower alanine levels compared to controls, suggesting that alanine was being consumed to support a further increased rate of metabolism. This supports the suggestion above that the additive effect of alanine in hadh-/-islets may be to provide pyruvate to allow completion of glutamate oxidation in the tricarboxylic acid (TCA) cycle, thus generating a greater increase in the ATP/ADP ratio than that produced by incomplete oxidation of glutamate via transdeamination into aspartate (see Figure 7) . Stimulation with 25 mM glucose alone partially reversed the lower basal levels of glutamate and of the sum of alanine, aspartate, glutamate and glutamine in hadh-/-compared to control islets. Stimulation by a combination of glucose plus AAM eliminated the differences in insulin release and amino acid levels between hadh-/-and +/+ islets that were seen with stimulation by AAM alone. This inhibitory effect on glucose on islet amino acid metabolism can be explained by our previous observation that glucose metabolism inhibits GDH activity and flux through GDH (11) (12) (13) . Interestingly, hadh-/-islets had reduced levels of GABA compared to controls under all conditions. This is similar to our observations in SUR1-/-islets or control islets exposed to glyburide (20) , in which reduced GABA levels correlate with decreased expression of glutamate decarboxylase. Glutamate decarboxylase gene expression was also found to be reduced in hadh-/-islets by both RT-PCR and real-time PCR analysis of islet mRNA (data not shown). As shown in Table 2 , glucagon responses were similar in hadh-/-and control islets, being stimulated only by the complete mixture of amino acids.
Interaction of SCHAD and GDH proteins-
Since the functional analysis of pancreatic islets suggested an activation of GDH activity in islets lacking SCHAD protein, we examined the possibility of protein-protein interactions between the two enzymes, reported by Filling, et al (21) , using liver mitochondria from hadh-/-and +/+ mice ( Figure 6 , Panels A and B). When anti-SCHAD antibody was used as bait ( Figure  6A ), GDH was co-precipitated with SCHAD in hadh+/+ mouse liver mitochondria, but not in -/-mice, consistent with a GDH-SCHAD protein complex in hadh+/+ liver mitochondria. When purified His-tagged SCHAD protein was used as bait, GDH was co-precipitated in hadh-/-liver extracts (Panel B, right lane), indicating that free GDH in hadh-/-liver mitochondria was readily available to form a protein complex with Histagged SCHAD protein. In contrast, in +/+ mice, the majority of GDH was associated with the endogenous SCHAD protein and unavailable to bind to His-tagged SCHAD (Panel B center lane).
Since SCHAD activity has been reported to be elevated in islets compared to liver (22), we measured SCHAD and GDH messenger RNA in hadh+/+ islets and liver by real-time PCR. The ratio of SCHAD to GDH message was 5-fold higher in islets than in liver (15 ± 1.3 vs. 2.7 ± 0.6, n=3, p < 0.01). As shown in Figure 6C , anti-GDH antibody was able to co-precipitate SCHAD in lysates of islets from hadh +/+ mice, confirming that SCHAD associated with GDH in islets, as well as liver.
Mass spectrometric analysis of the hadh-/-liver mitochondrial extract from the pull down assay illustrated in Figure 6B , using His-tagged SCHAD protein as bait, confirmed the presence of two GDH peptide fragments. The amino acid sequences of these two peptides were (K)IIAEGANGPTTPEADKIFLER(N) and (K)YNLGLDLR(T). Interestingly, GDH was not the only protein in liver mitochondria from hadh-/-mice that was pulled down by Histagged SCHAD.
Mass spectrometry also revealed the presence of peptides from several other mitochondrial proteins, including carbamoyl phosphate synthetase-1 and 3-hydroxy-3-methylglutaryl-CoA lyase.
The physiologic roles of these proteins are liver specific and are the subject of further investigation.
Islet GDH enzyme kinetics-To determine whether the absence of SCHAD protein altered GDH enzyme activity, we examined GDH and SCHAD activities in homogenates of islets, liver, and kidney. As shown in Table 3 , the ratio of SCHAD to GDH activities was markedly higher in islets compared to liver or kidney in hadh +/+ mice. As we had previously observed, latent GDH activity (maximum minus basal activity) was greater in islets compared to liver and kidney implying the presence of some inhibitory effect; but this was similar in hadh-/-and +/+ islets. The ED50s for allosteric inhibitors (GTP) and activators (ADP) were similar between -/-and +/+ mice in all three tissues. However, under conditions of submaximal stimulation with 10 µM ADP, the Km for alphaketoglutarate was reduced in hadh-/-islets, but was not changed in liver or kidney. This reduced Km for alpha-ketoglutarate in hadh-/-islets resulted in a 50% increase of enzyme efficiency as indicated by the ratio of Vmax to Km (0.4±0.04 vs. 0.6±0.05, p<0.05, n=4). In contrast, the Km for the second GDH substrate, ammonia, was unchanged in hadh-/-islets (data not shown). Islet GDH kinetics in the reverse, oxidative deamination, direction could not be measured, because, as expected, the reaction velocity was very low.
The increased affinity of GDH for alphaketoglutarate in hadh-/-islets was confirmed by adding back His-SCHAD protein to liver homogenate from -/-mice. As shown in Table 4 , increasing the His-SCHAD/GDH molar ratio (SCHAD dimmers to GDH hexamers) to 3.1 reduced the affinity of GDH for alphaketoglutarate by 2.8 fold. Since the Vmax remained unchanged, the addition of SCHAD protein to hadh-/-liver homogenate resulted in a 2.6 fold decrease in GDH enzyme efficiency. Similar results were also observed in mixing experiments using His-SCHAD and bovine GDH (data not shown). As shown in Table 4 , intermediate elevations of the SCHAD/GDH molar ratio did not affect the Km for alphaketoglutarate.
This may explain why the inhibitory effect of SCHAD on GDH was only found in islets, but not in kidney and liver, since islets contained the highest ratio of SCHAD to GDH in both gene expression and enzyme activity.
Discussion
These studies of mice with disruption of the SCHAD (hadh) gene demonstrate that they have a dysregulation of insulin secretion similar to the phenotype of hyperinsulinemic hypoglycemia reported in children with recessive inactivating mutations of HADH (also known as HAD1). In vivo, hadh-/-mice had reduced plasma glucose, increased plasma 3-hydroxy-butyrylcarnitine, and increased urinary 3-hydroxyglutarate, consistent with observations in affected children. In vitro studies of isolated islets from hadh-/-mice showed increased sensitivity to amino acid stimulated insulin secretion, indicating an activation of the glutaminolysis pathway through GDH to generate ATP and trigger release of insulin.
Immunoprecipitation experiments demonstrated binding of SCHAD to GDH and enzyme kinetic studies in islet homogenates showed that absence of SCHAD increases the enzymatic efficiency of GDH. These findings indicate that hyperinsulinism in SCHAD deficient mice is caused by loss of a "moonlighting" function of the SCHAD protein which normally provides a direct inhibitory effect on GDH enzymatic activity in pancreatic β-cells (Figure 7) .
A relationship between SCHAD deficiency and dysregulation of insulin secretion is clear in both humans and in mice. A total of 5 families have been reported with hyperinsulinism associated with SCHAD deficiency and we are aware of three additional unpublished cases (2) (3) (4) 23) . All of these cases had recessive mutations identified and most appear to be associated with absence of SCHAD protein, as well as enzymatic activity. It should be noted that other possible cases of SCHAD deficiency have been reported that did not have hyperinsulinism.
In some, low SCHAD enzymatic activity was found in tissues, but none had mutations of the HADH1 gene (24) (25) (26) . One reported case with partial enzyme deficiency was compound heterozygous for HADH1 missense mutations; in this case, the mutant protein was expressed in normal amounts and the child did not appear to have hyperinsulinism (27) . Kapoor et al. recently described protein sensitive hypoglycemia in three cases of SCHAD deficiency with hyperinsulinism (6). This observation agrees with our finding of increased sensitivity to amino acid stimulated insulin secretion in vivo and in isolated islets from hadh-/-mice (6). Two of Kapoor's cases had mutations compatible with complete absence of SCHAD protein. The third case with protein-sensitive hyperinsulinism had a homozygous missense mutation with only a 50% reduction in enzyme activity and no abnormal fatty acid metabolites; it is possible that this amino acid change has little effect on enzymatic activity, but interferes with the effect of the protein on GDH regulation.
SCHAD deficiency also appears to play a role in the hyperinsulinism associated with isletspecific knockout of the FOXa2 transcription factor (28) . Islets from these mice have reduced expression of both SCHAD and Kir6.2, one of the genes associated with the K ATP channel form of hyperinsulinism. This combined deficiency causes a more severe hypoglycemic phenotype than deficiency of K ATP alone, consistent with SCHAD deficiency having an independent role in causing hyperinsulinism.
Attempts to identify the mechanism of hyperinsulinism in SCHAD deficiency using RNA interference to suppress enzyme expression have yielded inconsistent results. Our colleagues, Hardy, et al, found increases in basal, but not in glucosestimulated insulin release when hadh was suppressed by RNA interference in INS 832/13 cells and in isolated mouse islets (29) ; the increased insulin release was not inhibited by diazoxide in the knocked-down cells, suggesting a K ATP -channel independent mechanism. In contrast, Pipeleers and colleagues (22) reported that knock-down of hadh did not affect basal secretion, but increased insulin responses to GSIS and to depolarization with KCl in both INS cells and in rat islet cells; they suggested that an amplifying effect on GSIS of fatty acylCoAs proximal to the SCHAD step was responsible for hyperinsulinism in SCHAD deficiency. In contrast to both of these reports, the present findings in the SCHAD knock-out mouse did not show changes in GSIS and neither of these knock-down studies addressed the protein-sensitivity in SCHAD deficiency which has recently been recognized to be an important feature of the disorder in children (6). The reasons for the different findings in the two studies with SCHAD knock-down are not clear, but an important factor may be the fact that both achieved only a partial, 50-80% reduction of SCHAD. Based on the reported cases of SCHAD deficiency associated with by guest on November 19, 2017 http://www.jbc.org/ Downloaded from hyperinsulinism, this is likely insufficient to reproduce the hyperinsulinism phenotype. In a child with missense SCHAD mutations that reduced enzyme activity to 10-20% of normal (similar to the residual SCHAD expression reported in the knock-down experiments), there was no evidence of hyperinsulinism (27) .
The present experiments suggest that the mechanism of insulin dysregulation associated with SCHAD deficiency is similar to that seen in children with activating mutations of GDH (30, 31) . These mutations impair allosteric inhibition of GDH by GTP, thus leading to increased oxidation of glutamate and insulin release.
Affected patients have increased sensitivity to activation of GDH by leucine, which is manifested clinically by hypoglycemia in response to ingestion of protein meals (32, 33) . These patients also have persistent hyperammonemia, possibly due to the activation of GDH enzyme activity in the liver or kidney (34) . Hyperammonemia is not a feature of SCHAD deficiency, perhaps because the activation of GDH may be limited to islets and also appears to be less severe than in GDH activating mutations.
Isolated hadh-/-islets demonstrate many similarities to those of islets expressing the H454Y activating mutation of GDH. Islets from both mouse models release insulin in response to a physiologic mixture of amino acids. Both show increased basal rates of glutaminolysis and a reduced threshold for leucine stimulation of insulin release, although the threshold in hadh-/-islets is intermediate between control and GDH transgenic islets (12) . Unlike GDH transgenic islets, hadh-/-islets failed to release insulin in response to glutamine alone, but required the presence of leucine at concentrations that are not stimulatory in control islets. For maximum insulin response, islets from hadh-/-mice required exposure to alanine, glutamine, and leucine. The effect of alanine addition may be attributed to its contribution via acetyl-CoA formation to stimulate ATP production from the oxidation of glutamate in the tricarboxylic acid cycle (20) (see Figure 7 ). These observations suggest that the degree of activation of GDH in hadh-/-is lower than in islets expressing the activating H454Y GDH; this may account for the somewhat milder hypoglycemia of hadh-/-mice compared to the GDH transgenic mouse.
We did not observe any abnormalities in the responses of islets from SCHAD deficient mice to the addition of fatty acids, including mediumchain fatty acids which are substrates for the action of SCHAD. Octanoate potentiated the effect of amino acids on the stimulation of insulin secretion in hadh-/-islets, but this was not different from its effect on GSIS in both control and -/-islets. The failure to observe a specific effect of fatty acids on insulin secretion in hadh-/-islets indicates that the hyperinsulinism is not the result of accumulation of fatty acid intermediates. It is also consistent with the fact that other genetic defects of mitochondrial fatty acid beta-oxidation do not cause hyperinsulinism (5) .
Measurements of cytosolic calcium responses to stimuli confirmed that the hyper-responsiveness of hadh-/-islets was specific to amino acid stimulation. Basal calcium concentrations and basal insulin secretion were normal in hadh-/-islets. This contrasts with islets from SUR1-/-mice which serve as a model for the recessive form of hyperinsulinism due to inactivating mutations of the β-cell K ATP channel. SUR1-/-islets lacking K ATP channel activity are constitutively depolarized and have elevated basal concentrations of cytosolic calcium (7) . In addition, patients with K ATP channel inactivation are unresponsive to treatment with diazoxide, a K ATP channel agonist, whereas patients with SCHAD deficiency respond well to diazoxide (2, 3, 6, 23) . Thus, the hyperinsulinism associated with SCHAD deficiency is not due to abnormalities of the K ATP channel. Cytosolic calcium responses to glucose stimulation showed subtle differences in hadh-/-islets ( Figure 5 ), which probably reflect increased metabolism of intracellular amino acids via GDH in the basal state (see also Table 2 ).
Our findings suggest that GDH activation in SCHAD deficiency is due to the loss of a direct protein-protein interaction between the two enzymes. This was demonstrated by both immunoprecipitation and protein pull-down experiments, confirming and extending observations recently reported by Filling et al. (21) . That SCHAD may have a regulatory effect on GDH via this protein-protein interaction could not have previously been anticipated. As noted above, with the possible exception of one of the cases described by Kapoor (6), it appears that cases of SCHAD deficiency without hyperinsulinism express normal amounts of enzyme protein whereas cases associated with hyperinsulinism lack SCHAD protein (including an unpublished case we have recently identified). This phenomenon, in which a protein has additional functions in other pathways has been termed moonlighting protein effects (35). As in the present experiments, mass spectrometry has been useful in detecting such interactions (35).
The pull-down experiments identified additional proteins that complex with SCHAD and GDH, including enzymes related to ureagenesis and ketogenesis, which might form a larger regulatory network. For example, although not detected in our SCHAD pull-downs, SIRT4, one of the sirtuin enzymes involved in calorie-restriction longevity, has been reported to associate with GDH and inhibit its activity by ADPribosylation (36) .
Our experiments indicate that SCHAD reduces the affinity of GDH for alpha-ketoglutarate, but for not ammonia, suggesting that the presence of SCHAD affects binding of the carboxyl end of the substrate in the catalytic site. The effect was limited to islet GDH, perhaps reflecting the high levels of SCHAD (22) and, especially, the high ratio of SCHAD to GDH in this tissue (Table 3) . It is interesting to speculate that the inhibitory effect of SCHAD on GDH might be part of a mechanism for reciprocal control of fatty acid and amino acid oxidation. Further work is clearly needed to define the details of how SCHAD modifies GDH activity, especially in islets.
In summary, the results of our studies of insulin dysregulation in hadh-/-mice provide an explanation for the hyperinsulinemic hypoglycemia reported in children with SCHAD deficiency. These mice display amino acid sensitive hypoglycemia in vivo. Their islets have abnormal sensitivity to amino acid stimulation of insulin secretion and demonstrate evidence of increased GDH activity, similar to islets expressing activating mutations of GDH. The activation of GDH appears to be related to a loss of a regulatory protein-protein interaction between GDH and SCHAD.
Abbreviations: SCHAD: short -chain 3-hydroxyacyl-CoA dehydrogenase; GDH, glutamate dehydrogenase; BCH, 2-amino-2-norbornane-carboxylic acid; GSIS, glucose stimulated insulin secretion; AASIS: amino acid stimulated insulin secretion; [Ca 2+ ] i : cytosolic calcium. Immunoprecipitation of SCHAD using anti-GDH antibody as bait in isolated islets. Western blotting with anti-SCHAD antibody detected SCHAD protein in T7-SCHAD protein (left lane) and +/+ islets lysate as controls. SCHAD was also detected from +/+ islets after immunoprecipitation with anti-GDH, but not in -/-islets. All studies were repeated 3 to 6 times and showed similar results. Fig.7 . Mechanism of insulin dysregulation in SCHAD deficiency. In SCHAD deficient islets, the loss of an inhibitory protein-protein interaction of SCHAD on GDH leads to an increase in the sensitivity of the GDH reaction to allosteric activation by leucine. Stimulation of islets by glutamine plus leucine in vitro produces a submaximal insulin response compared to stimulation with a complete physiologic mixture of amino acids, because glutamate trans-deamination to aspartate uses only part of the TCA cycle to generate ATP as a trigger for insulin release. Addition of alanine to stimulation by glutamine plus leucine produces a greater release of insulin, equal to that of a mixture of amino acids, since the TCA cycle can be completed to generate a greater ATP response (18 vs. 9 mol of ATP per mol of glutamate oxidized). Abbreviations: GDH = glutamate dehydrogenase, SCHAD = short -chain 3-hydroxyacyl-CoA dehydrogenase, α-KG = alpha-ketoglutarate, OAA = oxaloacetate, TCA = tricarboxylic acid. 
